This contrasts with NSCLC, where EML4-ALK (5%-7%) drives targeted therapy success,6 or TRK fusion-positive cancers, where NTRK inhibitors achieve high response rates.11 This evidence concerns the gene ALK and non-small cell lung carcinoma.